People
Ross Elfand is a seasoned antitrust trial lawyer who has served as lead and co-lead counsel in high profile matters on behalf of leading pharmaceutical and technology companies. He regularly represents companies as the lead advocate before competition enforcement agencies, including the Federal Trade Commission, state attorneys general offices, and other agencies around the world.
Ross often serves as co-lead counsel in large-scale, complex, and high-risk matters, including multi-district cartel and monopolization cases in the United States. He is a skilled litigator of claims involving the interplay between intellectual property and antitrust laws in the pharmaceutical industry.
Ross is a trusted legal advisor on antitrust risks associated with product development, contracting, marketing, joint ventures, and patent-related issues. He also advises companies in the technology industry regarding the intersection of global privacy and competition laws.
J.D., Brooklyn Law School, Magna Cum Laude
B.A., Emory University
New Jersey
New York
Supreme Court of the United States
U.S. Court of Appeals for the Second Circuit
U.S. District Court for the Eastern District of New York
U.S. District Court for the Southern District of New York
Law Clerk, Magistrate Judge Gabriel W. Gorenstein, U.S. District Court for the Southern District of New York
October 28, 2024
Antitrust Litigator Ross Elfand Joins King & Spalding in New York
Pharmaceutical Antitrust
Regeneron v. Novartis – Represented Novartis as co-lead counsel in antitrust litigation involving Walker Process monopolization claims relating to a patent covering syringes prefilled with an anti-VEGF drug that treats ophthalmic conditions.
Represented Pfizer as co-lead counsel in ground-breaking antitrust litigation regarding the impact of contracting and rebating practices on biosimilars.
In re Aggrenox Antitrust Litigation – Represented Boehringer lngelheim as co-lead counsel in class action multidistrict litigation arising from alleged delay in generic competition to Aggrenox, due to a claimed “reverse payment” patent settlement and obtained appellate victory in challenge to class action settlements.
See more
October 28, 2024
Antitrust Litigator Ross Elfand Joins King & Spalding in New York
Pharmaceutical Antitrust
Regeneron v. Novartis – Represented Novartis as co-lead counsel in antitrust litigation involving Walker Process monopolization claims relating to a patent covering syringes prefilled with an anti-VEGF drug that treats ophthalmic conditions.
Represented Pfizer as co-lead counsel in ground-breaking antitrust litigation regarding the impact of contracting and rebating practices on biosimilars.
In re Aggrenox Antitrust Litigation – Represented Boehringer lngelheim as co-lead counsel in class action multidistrict litigation arising from alleged delay in generic competition to Aggrenox, due to a claimed “reverse payment” patent settlement and obtained appellate victory in challenge to class action settlements.
See more
October 28, 2024
Antitrust Litigator Ross Elfand Joins King & Spalding in New York
J.D., Brooklyn Law School, Magna Cum Laude
B.A., Emory University
New Jersey
New York
Supreme Court of the United States
U.S. Court of Appeals for the Second Circuit
U.S. District Court for the Eastern District of New York
U.S. District Court for the Southern District of New York
Law Clerk, Magistrate Judge Gabriel W. Gorenstein, U.S. District Court for the Southern District of New York